^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Aybintio (bevacizumab biosimilar)

    i
    Other names: SB8, SP-8
    Company:
    3SBio, Mundipharma, Samsung
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    4ms
    Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Oct 2024 --> Dec 2023
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • docetaxel • Aybintio (bevacizumab biosimilar) • MK-4830
    6ms
    Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Dec 2024
    Enrollment closed • Trial completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • docetaxel • Aybintio (bevacizumab biosimilar) • MK-4830
    11ms
    BRISK: A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (clinicaltrials.gov)
    P2, N=32, Recruiting, Asan Medical Center
    New P2 trial • Metastases
    |
    FH (Fumarate Hydratase)
    |
    Avastin (bevacizumab) • erlotinib • Aybintio (bevacizumab biosimilar)